Carcinoma, Non-Small-Cell Lung

797 clinical trials · Condition

Record	Firm	Date
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer (NCT00035152)	Bristol-Myers Squibb	2000-06-01
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer (NCT02204059)	Boehringer Ingelheim	1999-12-01
Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer (NCT00178256)	University of Rochester	1998-06-01
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer (NCT00001499)	National Cancer Institute (NCI)	1996-03-01
Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC (NCT00001450)	National Cancer Institute (NCI)	1995-09-01
Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy (NCT00063219)	Wyeth is now a wholly owned subsidiary of Pfizer
Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer (NCT00040560)	Copharos
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC) (NCT00034957)	Pfizer
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) (NCT00092924)	Human Genome Sciences Inc.
An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations (NCT04535557)	Millennium Pharmaceuticals, Inc.
Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer (NCT00067548)	Wyeth is now a wholly owned subsidiary of Pfizer
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) (NCT01931306)	Boehringer Ingelheim
Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer (NCT00464282)	Gunma University
Utility of Anatometabolic Imaging for Radiation Treatment Planning for Lung Cancer (NCT00005666)	National Center for Research Resources (NCRR)
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) (NCT00054795)	Pharmacyclics LLC.
Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer (NCT00251498)	Veeda Oncology
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer (NCT00049790)	CASI pharmaceuticals, Inc.
64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab (NCT01006226)	Washington University School of Medicine
LUX Lung Special Access Scheme Australia Named Patient Use (NPU) (NCT01209650)	Boehringer Ingelheim
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma (NCT00051571)	Seagen Inc.
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor (NCT05225259)	Eli Lilly and Company
Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC (NCT02824094)	Pfizer
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV (NCT01674738)	Aktion Bronchialkarzinom e.V.

Track Carcinoma, Non-Small-Cell Lung automatically

Every clearance here is in the API, with alerts when new ones post.